Gene-Guided chemo aims to boost surgery success in stomach cancer
NCT ID NCT02366819
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot trial tests whether using a patient's genetic profile to determine the dose of irinotecan (a chemotherapy drug) can improve outcomes for people with advanced stomach or esophageal cancer. The study combines chemotherapy before and after surgery, with the goal of increasing the chance of a complete tumor removal. It involves 36 participants and is currently suspended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chemotherapy drugs (oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil) plus surgery
What this could lead to
If successful, this could show that tailoring chemo doses based on a patient's genes reduces side effects and improves the chance of successful surgery.
What could go wrong
This is a small pilot trial (36 people) that has been suspended, so results are uncertain. The approach may not work for all patients or may still cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kellogg Cancer Center - Evanston Hospital
Evanston, Illinois, 60201, United States
-
NorthShore University HealthSystem
Evanston, Illinois, 60201, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States